

Protect normal cells while cisplatin and radiation attack

- Reduce the severity of xerostomia & nephrotoxicity^{1,2}
- Help limit treatment delays or discontinuations¹

Approved Indications

- ETHYOL® (amifostine) is indicated to reduce the incidence of moderate to severe xerostomia in patients undergoing postoperative radiation treatment for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands.
- ETHYOL is indicated to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer or non-small-cell lung cancer.
- For the approved indications, the clinical data do not suggest that the effectiveness of cisplatin-based chemotherapy regimens or radiation therapy is altered by ETHYOL. There are at present only limited data on the effects of ETHYOL on the efficacy of chemotherapy or radiotherapy in other settings. ETHYOL should not be administered to patients in other settings where chemotherapy can produce a significant survival benefit or cure, or in patients receiving definitive radiotherapy, except in the context of a clinical study.

Safety Information

- In a radiotherapy clinical trial, the most common side effects with ETHYOL were nausea/vomiting (53%) and hypotension (15%). In a chemotherapy clinical trial, the most common side effects with ETHYOL were nausea/vomiting (96%) and hypotension (61%).
- Patients who are hypotensive or dehydrated should not receive ETHYOL. Patients who are taking antihypertensive therapy that cannot be stopped for 24 hours preceding ETHYOL administration should not receive ETHYOL at doses recommended for chemotherapy. Blood pressure should be monitored during treatment. Serum calcium levels should be monitored in patients at risk for hypocalcemia.
- Allergic manifestations including anaphylaxis and severe cutaneous reactions have been associated rarely with ETHYOL administration. ETHYOL should be permanently discontinued for serious or severe cutaneous reactions alone and when associated with fever.
- ETHYOL is contraindicated in patients with known sensitivity to aminothiols compounds.

Please see brief summary of Prescribing Information on adjacent page.

Ethyol
AMIFOSTINE
for Injection
Selective Protection

References:

1. Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. *J Clin Oncol.* 1996;14:2101-2112. 2. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. *J Clin Oncol.* 2000;18:3339-3345.